SEC Form 3 · accession 0001209191-16-110692
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edgar Engleman
Director · 10% Owner
Period of report
Mar 22, 2016
Accepted (ET)
Mar 25, 2016 · 8:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 1,587,960 | I | See footnote 1 | |
| Common StockF2 | holding | — | — | — | 11,632 | I | See footnote 2 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares are held by Vivo Ventures Fund VI, L.P. ("Fund VI"). The Reporting Person is a managing partner at Vivo Ventures VI, LLC, the general partner of both Fund VI and Vivo Ventures VI Affiliates Fund, L.P. ("Affiliates Fund"). The Reporting Person has shared voting or investment power over the shares held by Fund VI and Affiliates Fund and disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
- F2Shares are held by Vivo Ventures VI Affiliates Fund, L.P. ("Affiliates Fund"). The Reporting Person is a managing partner at Vivo Ventures VI, LLC, the general partner of both Vivo Ventures Fund VI, L.P. ("Fund VI") and Affiliates Fund. The Reporting Person has shared voting or investment power over the shares held by Fund VI and Affiliates Fund and disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.